Urinalysis market growth is driven by the increasing burden of UTIs, diabetes, and kidney & liver diseases; rising geriatric population and the subsequent increase in age-associated diseases and increasing adoption of POC diagnostic tests.
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents.
𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐆𝐫𝐚𝐛 𝐏𝐃𝐅 @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153479294
COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers face unprecedented challenges. Regulatory authorities utilized methods to speed approval of diagnostic products. Companies have taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities.
Due to rapid growth in the senior population, the prevalence of age-associated diseases such as diabetes, liver, and kidney diseases are expected to increase significantly. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for tests such as creatinine, albumin, glucose, ketones, and bilirubin, etc.
The high investments in healthcare and life sciences research in emerging markets play an essential role in upgrading laboratory infrastructure in these countries. This, in turn, supports the installation of diagnostic systems in laboratories and leads to the growth of the urinalysis market.
In the absence of well-grounded regulatory frameworks, there may be an influx of low-quality and refurbished products into the economy. Considering these factors, the demand for refurbished analyzers can be expected to increase in the coming years, as these systems offer the same functionalities at a lower cost.
For More Info, Speak To Our Expert @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=153479294
The urinalysis market is segmented into disease screening and pregnancy and fertility. In 2020, the disease screening segment accounted for the largest share. This can be attributed to the increasing incidence of UTIs, diabetes, liver diseases and kidney ailments worldwide.
COVID-19 Impact Analysis on Urinalysis Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2019-2027.
The report encompasses data regarding market share and recent developments by key players.
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the ARKRAY, Inc., Alere, Inc., Mindray, Bio-Rad, Siemens Healthcare, Roche Diagnostics, and Sysmex.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Urinalysis Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/urinalysis-market/download-sampleMarket SegmentationThe broad Urinalysis market has been sub-grouped into the Product, Application, End-Userand region.
The report studies these subsets with respect to the geographical segmentation.
